Pamela F Weiss1, Andrew J Klink, Russell Localio, Matt Hall, Kari Hexem, Jon M Burnham, Ron Keren, Chris Feudtner. 1. Division of Rheumatology, Children's Hospital of Philadelphia, and Department of Pediatrics, Center for Clinical Epidemiology and Biostatistics, Leonard Davis Institute of Health Economics, University of Pennsylvania School of Medicine, Room 1539, North Campus, 3535 Market St, Philadelphia, PA 19104, USA. weisspa@email.chop.edu
Abstract
OBJECTIVE: To characterize the effect of corticosteroid exposure on clinical outcomes in children hospitalized with new-onset Henoch-Schönlein purpura (HSP). PATIENTS AND METHODS: We conducted a retrospective cohort study of children discharged with an International Classification of Diseases, Clinical Modification code of HSP between 2000 and 2007 by using inpatient administrative data from 36 tertiary care children's hospitals. We used stratified Cox proportional hazards regression models to estimate the relative effect of time-varying corticosteroid exposure on the risks of clinical outcomes that occur during hospitalization for acute HSP. RESULTS: During the 8-year study period, there were 1895 hospitalizations for new-onset HSP. After multivariable regression modeling adjustment, early corticosteroid exposure significantly reduced the hazard ratios for abdominal surgery (0.39 [95% confidence interval (CI): 0.17-0.91]), endoscopy (0.27 [95% CI: 0.13-0.55]), and abdominal imaging (0.50 [95% CI: 0.29-0.88]) during hospitalization. CONCLUSIONS: In the hospital setting, early corticosteroid exposure was associated with benefits for several clinically relevant HSP outcomes, specifically those related to the gastrointestinal manifestations of the disease.
OBJECTIVE: To characterize the effect of corticosteroid exposure on clinical outcomes in children hospitalized with new-onset Henoch-Schönlein purpura (HSP). PATIENTS AND METHODS: We conducted a retrospective cohort study of children discharged with an International Classification of Diseases, Clinical Modification code of HSP between 2000 and 2007 by using inpatient administrative data from 36 tertiary care children's hospitals. We used stratified Cox proportional hazards regression models to estimate the relative effect of time-varying corticosteroid exposure on the risks of clinical outcomes that occur during hospitalization for acute HSP. RESULTS: During the 8-year study period, there were 1895 hospitalizations for new-onset HSP. After multivariable regression modeling adjustment, early corticosteroid exposure significantly reduced the hazard ratios for abdominal surgery (0.39 [95% confidence interval (CI): 0.17-0.91]), endoscopy (0.27 [95% CI: 0.13-0.55]), and abdominal imaging (0.50 [95% CI: 0.29-0.88]) during hospitalization. CONCLUSIONS: In the hospital setting, early corticosteroid exposure was associated with benefits for several clinically relevant HSP outcomes, specifically those related to the gastrointestinal manifestations of the disease.
Authors: M C Calviño; J Llorca; C García-Porrúa; J L Fernández-Iglesias; P Rodriguez-Ledo; M A González-Gay Journal: Medicine (Baltimore) Date: 2001-09 Impact factor: 1.889
Authors: Pamela F Weiss; Andrew J Klink; Kari Hexem; Jon M Burnham; Mary B Leonard; Ron Keren; Russell Localio; Chris Feudtner Journal: J Pediatr Date: 2009-07-29 Impact factor: 4.406
Authors: Brian T Fisher; Tracey Harris; Kari Torp; Alix E Seif; Ami Shah; Yuan-Shung V Huang; L Charles Bailey; Leslie S Kersun; Anne F Reilly; Susan R Rheingold; Dana Walker; Yimei Li; Richard Aplenc Journal: Med Care Date: 2014-01 Impact factor: 2.983
Authors: Tellen D Bennett; Mark Fluchel; Aimee O Hersh; Kristen N Hayward; Adam L Hersh; Thomas V Brogan; Rajendu Srivastava; Bryan L Stone; E Kent Korgenski; Michael B Mundorff; T Charles Casper; Susan L Bratton Journal: Arthritis Rheum Date: 2012-12
Authors: Alix E Seif; Brian T Fisher; Yimei Li; Kari Torp; Douglas P Rheam; Yuan-Shung V Huang; Tracey Harris; Ami Shah; Matthew Hall; Evan S Fieldston; Marko Kavcic; Marijana Vujkovic; L Charles Bailey; Leslie S Kersun; Anne F Reilly; Susan R Rheingold; Dana M Walker; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2013-11-19 Impact factor: 3.167